In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf277 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Christina Koenig und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Pyelonephritis, Enterobacteriaceae, Cystitis. Die Arbeit nennt 20 Literaturangaben. Gefördert von: HHS, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority.
Abstract (Originalsprache)
Background
Ledaborbactam is an investigational oral β-lactamase inhibitor that restores ceftibuten's activity against strains of Enterobacterales expressing ESBLs and serine carbapenemases, offering a potential oral therapeutic option for cUTIs.
Objectives
To characterize the activity of ceftibuten-ledaborbactam human simulated regimens (HSRs) against β-lactamase-producing Enterobacterales in a murine urinary tract infection (UTI) model assessing infection in both the kidney and bladder.
Methods
Ten urogenic Enterobacterales (ceftibuten-ledaborbactam MIC ≤0.03 to 4 mg/L; ESBL, KPC, OXA-48) were assessed. Murine HSRs for oral ceftibuten (400 mg q8 h and 600 mg q12 h) alone and combined with oral ledaborbactam (400 mg q8 h and 600 mg q12 h) were developed. Activity was assessed by absolute bacterial burden (log10 cfu) in kidneys and bladders after 24 h of treatment.
Results
Mean (±SD) bacterial burdens in kidneys and bladders of mice at the start of dosing (0 h control) were 5.54 ± 0.22 and 2.95 ± 0.39 log10 cfu/tissue, respectively, which increased to >9 and >5.5 log10 cfu/tissue after 24 h. Ceftibuten monotherapy demonstrated similar growth compared to saline-dosed controls. Ceftibuten-ledaborbactam activity resulted in bacterial burden ranging from 3.56 to 6.44 log10 cfu/kidney for the q8 h regimen and 4.09–5.94 log10 cfu/kidney for the q12 h regimen across nine isolates with MIC ≤ 0.5 mg/L. In bladders, a bacterial burden of 2.00–3.92 log10 cfu was observed across treatment groups. As anticipated, the high MIC strain (4 mg/L), displayed only a moderate bacterial burden reduction in the kidney and bladder after treatment.
Conclusion
HSR exposures of ceftibuten-ledaborbactam administered q8 h and q12 h resulted in similar and marked bacterial reduction in an upper (kidney) and lower (bladder) UTI model caused by a variety of multi-drug resistant Enterobacterales.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA.
- Department of Intensive Care Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
- Center for Diagnostic Innovation, Pathology and Lab Medicine, Children's Hospital of Philadelphia, PA 19104, USA, Previously with Venatorx Pharmaceuticals, Malvern, PA, USA.
- Division of Infectious Diseases, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA.
ORCID-Profile: Tomefa E Asempa
Förderung
- HHS
- Administration for Strategic Preparedness and Response
- Biomedical Advanced Research and Development Authority
- Department of Health and Human Services
Zitieren
APA
Koenig, C., Yi, F., Nicolau, D. P., & Asempa, T. E. (2025). In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf277
Vancouver
Koenig C, Yi F, Nicolau DP, Asempa TE. In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf277
BibTeX
@article{Koenig2025,
author = {Koenig, Christina and Yi, Fan and Nicolau, David P and Asempa, Tomefa E},
title = {In vivo activity of ceftibuten-ledaborbactam oral combination against serine-β-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf277}
}
EUVIMED